Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Large Fraction RT, GM-CSF, Lenalidomide, and Glofitamab in R/R DLBCL
NCT06651853Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Xiamen University. Started Oct 2024; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06651853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651853.